Completed PHASE3 INTERVENTIONAL 2-arm NCT00603642

P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

A Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

Sponsor: Amgen

Conditions Idiopathic Thrombocytopenic Purpura

Interventions AMG 531 Placebo

Updated 9 times since 2017 Last updated: Nov 4, 2022 Started: Oct 1, 2007 Primary completion: Apr 13, 2009 Completion: Apr 13, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Idiopathic Thrombocytopenic Purpura and is currently completed. Amgen leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2022 [monthly]

Completed PHASE3
Jun 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Nov 2018 — Jun 2019 [monthly]

Completed PHASE3
Sep 2018 — Nov 2018 [monthly]

Completed PHASE3
Jun 2018 — Sep 2018 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.